THE PREPARATION OF NOVEL MEMBRANE PERMEATION ENHANCERS

Award Information
Agency:
Department of Health and Human Services
Branch
n/a
Amount:
$50,000.00
Award Year:
1988
Program:
SBIR
Phase:
Phase I
Contract:
n/a
Agency Tracking Number:
8015
Solicitation Year:
n/a
Solicitation Topic Code:
n/a
Solicitation Number:
n/a
Small Business Information
California Biotechnology Inc
2450 Bayshore Frontage, Mountain View, CA, 94043
Hubzone Owned:
N
Socially and Economically Disadvantaged:
N
Woman Owned:
N
Duns:
n/a
Principal Investigator:
() -
Business Contact:
() -
Research Institution:
n/a
Abstract
THE LONG-TERM OBJECTIVE OF THE RESEARCH PROPOSED IN THIS SBIR GRANT APPLICATION IS TO DEVELOP A TRANSMUCOSAL DELIVERYTECHNOLOGY WHICH WILL ELIMINATE THE NECESSITY FOR THE PARENTERAL ADMINISTRATION OF PROTEIN AND PEPTIDE DRUGS. THEGOALS OF THE PHASE I PROGRAM ARE TO SYNTHESIZE, PHYSICALLY CHARACTERIZE AND EVALUATE IN AN ANIMAL MODEL A NOVEL CLASS OF MEMBRANE PERMEATION ENHANCERS BASED ON THE FUSIDIC ACID NUCLEUS. THE NOVEL COMPOUNDS ARE MEANT TO COMPLEMENT AND IMPROVE UPON CALIFORNIA BIOTECHNOLOGY'S PROPRIETARY ENHANCER, SODIUM TAURODIHYDROFUSIDATE. THE SYNTHESIS OF THESE COMPOUNDS WILL BE CARRIED OUT USING CONVENTIONAL SYNTHETIC PROCEDURE. THE C-21 CARBOXYLATE OF THE FUSIDIC ACID NUCLEUS WILL BE CONVERTED TO AN ANHYDRIDE AND THEN REACTED WITH THE DESIRED MOLECULE TO GIVE AN AMIDE LINKED FUSIDATE DERIVATIVE. THE CMC, CMT AND THE PKA OF EACH ENHANCER MOLECULE WILL BE DETERMINED. USING INSULIN AND BETA-INTERFERON AS MODEL PROTEINS, THE ABILITY OF THESE MOLECULES TO ENHANCE ABSORPTION ACROSS THE NASAL MUCOSA WILL BE EVALUATED IN A RAT MODEL. THE WIDESPREAD USE OF PROTEINS AND PEPTIDES AS THERAPEUTICS IS DEPENDENT ON FINDING AN ALTERNATE TO PARENTERAL ADMINISTRATION. THE POTENTIAL MARKET FOR EFFECTIVE, NON-TOXIC PERMEATION ENHANCERS IS EXPECTED TO BE ENORMOUS.

* information listed above is at the time of submission.

Agency Micro-sites

US Flag An Official Website of the United States Government